Therapeutic potential of blockade of the urotensin II system in system hypertension

Current Hypertension Reports

Volumn 9, Issue 1, 2007, Pages 53-58

  Krum, Henry ^a   Kemp, Will ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACT 058362; ANTIHYPERTENSIVE AGENT; ENDOTHELIN 1; MESSENGER RNA; PALOSURAN; PLACEBO; SB 611812; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR ANTAGONIST;

BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CLINICAL TRIAL; CORRELATION ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART FAILURE; HUMAN; HYPERTENSION; IONTOPHORESIS; KIDNEY DISEASE; MICROCIRCULATION; MITOGENESIS; NONHUMAN; OSMOREGULATION; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; KIDNEY DISEASES; RECEPTORS, G-PROTEIN-COUPLED; UROTENSINS; VASOCONSTRICTION;

EID: 34047250447     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0010-x     Document Type: Review

References (50)

1. Bern H, Pearson D, Larson B, Nishioka R: Complete amino acid sequence of urotensin I, a hypotensive and corticotropin-releasing neuropeptide from Catostomus. Recent Prog Horm Res 1985, 41:533-552.
2. Elshoubagy N, Douglas S, Shabon U, et al.: Molecular and pharmacological characteristics of genes encoding urotensin II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 2002, 136:9-22.
3. Coulouarn Y, Jegou S, Tostivint H, et al.: Cloning, sequence analysis and tissue distribution of the mouse and rat urotcnsin II precursors. FEBS Lett 1999, 457:28-32.
4. Pearson D, Shively J, Clark B, et al.: Urotensin 11: a somatostatin-like peptide in the caudal neurosectretory system of fishes. Proc Natl Acad Sci U S A 1980, 77:5021-5024.
5. Krum H, Kompa A, Hannan R, Thomas W: Emerging role of the urotensin II system in cardiovascular disease. Heart Drug 2003, 3:153-158.
6. Carotenuto A, Grieco P, Campiglia P, et al.: Unraveling the active confirmation of urotensin II. J Med Chem 2004, 47:1652-1661.
7. Bern H, Pearson D, Larson B, Nishioka R: Neurohormones from fish tails: the caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory system of fishes. Recent Prog Hormone Res 1995, 41:533-552.
8. Douglas S, Dhanak D, Johns D: From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 2004, 25:76-85.
9. Flohr S, Kurtz M, Kostenis E, et al.: Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 2002, 45:1799-1805.
10. Wilson S, Bergsma D, Chambers J, et al.: Orphan G-protein-coupled receptors: the next generation of drug targets? Br J Pharmacol 1998, 125:138 7-1392.
11. Liu Q, Pong SS, Zeng Z, et al.: Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 1999, 266:174-178.
12. Maguire J, Davenport A. Is urotensin II the new endothelin? Br J Pharmacol 2002, 137:579-588.
13. Sauzeau V, Mellionnec E, Bertoglio J, et al.: Human urotensin II nduced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-Kinase. Circ Res 2001, 88:1102-1104.
14. Mori M, Sugo T, Abe M, et al.: Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Comm 1999, 265:123-129.
15. Totsune K, Takahashi K, Arihara Z, et al.: Role of urotensin II in patients on dialysis. Lancet 2001, 358:810-811.
16. Ames RS, Sarau HM, Chambers JK, et al.: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999, 401:282-286.
17. Behm D, Harrison S, Ao Z, et al.: Deletion of the UT receptor gene results in the selective loss of urotensin II contractile activity in the aortae isolated from UT receptor knockout mice. Br J Pharmacol 2003, 139:464-472.
18. Stirrat A, Gallagher M, Douglas S, et al.: Potent vasodilatory responses to human urotensin II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001, 280:H92S-H928.
19. Hillier C, Berry C, Petrie M, et al.: Effects of urotensin II in human arteries and veins of varying calibre. Circulation 2001, 103:1378-1381.
20. Maguire J, Kuc R, Davenport A: Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasconstrictor responses with endothelin-1. Br J Pharmacol 2000, 131:441-446.
21. Russell F, Molenaar P, O'Brien D: Cardiostimulant effects of urotenin II in human heart in vitro. Br J Pharmacol 2001, 132:5-9.
22. Douglas S, Sulpizio A, Piercy V, et al.: Differential vasoconstrictor activity of human urotensin II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000, 131:1262-1274.
23. Gardiner S, March J, Kemp P, et al.: Depressor and regionally selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 2001, 132:162S-1629.
24. Lin Y, Tsuchihashi T, Matsumura K, et al.: Central cardiovascular action of urotensin II in conscious rats. J Hypertens 2003, 21:159-165.
25. Wilkinson I, Affolter J, de Haas S, et al.: High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002, 53:341-347.
26. Affolter J, Newby D, Wilkinson I, et al.: No effect on central or peripheral blood pressure or systemic urotensin II infusion in humans. Br J Clin Pharmacol 2002, 54:617-621.
27. Bohm F, Pernow J: Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002, 135:25-27.
28. Douglas S: Human urotensin 11 as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? Curr Opin Pharmacol 2003, 3:159-167.
29. Lim M, Honisett S, Sparkes C, et al.: Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 2004, 109:1212-1214.
30. Abdelrahman A, Pang C: Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci 2002, 71:819-82S.
31. Zhang A, Chen Y, Zhang D, et al.: Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 2003, 285:17792-17798.
32. Cheung B, Leung R, Bun Man Y, Wong L: Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004, 22:1341-1344.
33. Matsushita M, Shichiri M, Imai T, et al.: Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissue. J Hypertens 2001, 19:2185-2190.
34. Sondermeijer B, Kompa A, Komesaroff P, Krum H: Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 2005, 18:1195-1199.
35. Watanabe T, Pakala R, Katagiri T, Benedict C: Synergistc effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 2001, 19:2191-2196.
36. Russell F, Molenaar P: Cardiovascular actions of human urotensin II - considerations for hypertension. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:274-280.
37. Totsune K, Takahashi K, Arihara Z, et al.: Role of urotensin II in patients on dialysis. Lancet 2001, 358:810-811.
38. Langham R, Kelly DJ, Gow RM, et al.: Increased expression of urotensin II and urotensin receptor in human diabetic nephropathy. Am J Kidney Dis 2004, 44:826-831.
39. Tzanidis A, Hannan RD, Thomas WG, et al.: Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003, 93:246-253.
40. Ng L, Loke I, O'Brien R, et al.: Plasma urotensin in human systolic heart failure. Circulation 2002, 106:2877-2880.
41. Richards A, Nicholls M, Lainchbury J, et al.: Plasma urotensin II in heart failure. Lancet 2002, 360:545-546.
42. Russell F, Meyers D, Galbraith A, et al.: Elevated plasma levels of human urotensin II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003, 285:H1576-H1581.
43. Douglas S, Tayara L, Ohlstein E, et al.: Congestive heart failure and expression of myocardial urotensin II. Lancet 2002, 359:1990-1997.
44. Behm D, Herold C, Ohlstein E, et al.: Pharmacological characterisation of SB-7104011 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin II receptor antagonist. Br J Pharmacol 2002, 137.449-458.
45. Camarda V, Guerrini R, Kostenis E, et al.: A new ligand for the urotensin II receptor. Br J Pharmacol 2002, 137.311-314.
46. Herold C, Behm D, Buckley P, et al.: The neuromedin B receptor antagonist BIM-23127 is a potent antagonist at human and rat urotensin II receptors. Br J Pharmacol 2003, 139:203-207.
47. Clozel M, Binkert C, Birker-Robaczewska M, et al.: Pharmacology of the urotensin II receptor antagonist ACT-058362: first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 2004, 311:204-212.
48. Sidharta PN, Wagner FD, Bohnemeier H, et al.: Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 2006, 80:246-256.
49. Bousette N, Hu F, Ohlstein EH, et al.: Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 2006, 41:285-295.
50. Palosuran in Clinical Development. Available at: http://www.actelion.com/ www/www_main_p.nsf/Content/Other+Projects+in+Clinical+Development.